Talphera Inc
NASDAQ:TLPH

Watchlist Manager
Talphera Inc Logo
Talphera Inc
NASDAQ:TLPH
Watchlist
Price: 1.23 USD 6.03% Market Closed
Market Cap: 57.3m USD

Talphera Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Talphera Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Talphera Inc
NASDAQ:TLPH
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
51%
CAGR 10-Years
31%
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
EPS (Diluted)
$2
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

Talphera Inc
Glance View

Market Cap
56.1m USD
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The firm's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The firm is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

TLPH Intrinsic Value
Not Available

See Also

What is Talphera Inc's EPS (Diluted)?
EPS (Diluted)
-0.3 USD

Based on the financial report for Sep 30, 2025, Talphera Inc's EPS (Diluted) amounts to -0.3 USD.

What is Talphera Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
31%

Over the last year, the EPS (Diluted) growth was 34%.

Back to Top